ArticleJAMA network open2021
Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- An assessment of the prevalence of cannabis use in eye clinic patients and its implications on glaucoma diagnosis and management.International ophthalmology · 2025Article
- What proportion of people who use cannabis in Germany have spoken with their general practitioner about their consumption? A repeated cross-sectional representative population survey.Journal of cannabis research · 2025Article
- Why is substance use missing from my patient's problem list? CTN research to advance screening, prevention, and treatment of substance use in primary care.Journal of substance use and addiction treatment · 2025Article
- The Combined Relationship of Prescription Drug Monitoring Program Enactment and Medical Cannabis Laws with Chronic Pain-Related Healthcare Visits.Journal of general internal medicine · 2025Article
- NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.Neuropsychopharmacology reports · 2025Article
- An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.Pharmaceutics · 2025Review
- Discussions of Cannabis Over Patient Portal Secure Messaging: Content Analysis.Journal of medical Internet research · 2024Article
- Cannabis Use Reported by Patients Receiving Primary Care in a Large Health System.JAMA network open · 2024Article
- Medicinal cannabis use among young adults during California's transition from legalized medical use to adult-use: a longitudinal analysis.The American journal of drug and alcohol abuse · 2024Article
- Trends in past-month cannabis use among US adults across a range of disabilities and health conditions, 2015-2019.Preventive medicine · 2023Article
- A Pragmatic, Person-Centered View of Cannabis in the United States: Pursuing Care That Transcends Beliefs.Substance abuse · 2023Review
- Association between cannabis use disorder symptom severity and probability of clinically-documented diagnosis and treatment in a primary care sample.Drug and alcohol dependence · 2023Observational
- Is it time for a cannabis harm reduction approach? Commentary on Sherman et al. (2022) and Borodovsky et al. (2022).Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023Review
- Cannabis dispensary staff approaches to counseling on potential contraindications to cannabis use: insights from a national self-report survey.BMC primary care · 2023Article
- Effects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain.Annals of internal medicine · 2023Article
- Cannabis and nicotine co-use among primary care patients in a state with legal cannabis access.Addictive behaviors · 2023Article
- Validity of the Single-Item Screen-Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care.JAMA network open · 2022Article
- Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state.Substance abuse treatment, prevention, and policy · 2022Article
- Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients.JAMA network open · 2022Article
- Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation.European journal of public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Importance: Many people use cannabis for medical reasons despite limited evidence of therapeutic benefit and potential risks. Little is known about medical practitioners' documentation of medical cannabis use or clinical characteristics of patients with documented medical cannabis use. Objectives: To estimate the prevalence of past-year medical cannabis use documented in electronic health records (EHRs) and to describe patients with EHR-documented medical cannabis use, EHR-documented cannabis use without evidence of medical use (other cannabis use), and no EHR-documented cannabis use. Design, Setting, and Participants: This cross-sectional study assessed adult primary care patients who completed a cannabis screen during a visit between November 1, 2017, and October 31, 2018, at a large health system that conducts routine cannabis screening in a US state with legal medical and recreational cannabis use. Exposures: Three mutually exclusive categories of EHR-documented cannabis use (medical, other, and no use) based on practitioner documentation of medical cannabis use in the EHR and patient report of past-year cannabis use at screening. Main Outcomes and Measures: Health conditions for which cannabis use has potential benefits or risks were defined based on National Academies of Sciences, Engineering, and Medicine's review. The adjusted prevalence of conditions diagnosed in the prior year were estimated across 3 categories of EHR-documented cannabis use with logistic regression. Results: A total of 185 565 patients (mean [SD] age, 52.0 [18.1] years; 59% female, 73% White, 94% non-Hispanic, and 61% commercially insured) were screened for cannabis use in a primary care visit during the study period. Among these patients, 3551 (2%) had EHR-documented medical cannabis use, 36 599 (20%) had EHR-documented other cannabis use, and 145 415 (78%) had no documented cannabis use. Patients with medical cannabis use had a higher prevalence of health conditions for which cannabis has potential benefits (49.8%; 95% CI, 48.3%-51.3%) compared with patients with other cannabis use (39.9%; 95% CI, 39.4%-40.3%) or no cannabis use (40.0%; 95% CI, 39.8%-40.2%). In addition, patients with medical cannabis use had a higher prevalence of health conditions for which cannabis has potential risks (60.7%; 95% CI, 59.0%-62.3%) compared with patients with other cannabis use (50.5%; 95% CI, 50.0%-51.0%) or no cannabis use (42.7%; 95% CI, 42.4%-42.9%). Conclusions and Relevance: In this cross-sectional study, primary care patients with documented medical cannabis use had a high prevalence of health conditions for which cannabis use has potential benefits, yet a higher prevalence of conditions with potential risks from cannabis use. These findings suggest that practitioners should be prepared to discuss potential risks and benefits of cannabis use with patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.